icaspase9-transduced t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01494103)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Epstein-Barr Virus Infections · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lymphohistiocytosis, Hemophagocytic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoproliferative Disorders · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- icaspase9-transduced t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01494103 | Phase 1 | Nov 1, 2011 | Baylor University, Methodist Cancer Center, Houston, Texas |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1